Turning back the cellular clock has been shown in dishes and in mice. Humans are still at the blueprint stage.
No contact with the clinic yet. The biggest question isn't efficacy — it's cancer.
The widest gap between evidence and investment on the map. Only capital that can wait a long time gets in.